2017
DOI: 10.1002/cpt.672
|View full text |Cite
|
Sign up to set email alerts
|

An Accelerator Mass Spectrometry‐Enabled Microtracer Study to Evaluate the First‐Pass Effect on the Absorption of YH4808

Abstract: C-labeled YH4808, a novel potassium-competitive acid blocker, was intravenously administered as a microtracer at 80 μg (11.8 kBq or 320 nCi) concomitantly with the nonradiolabeled oral drug at 200 mg to determine the absolute bioavailability and to assess the effect of pharmacogenomics on the oral absorption of YH4808. The absolute bioavailability was low and highly variable (mean, 10.1%; range, 2.3-19.3%), and M3 and M8, active metabolites of YH4808, were formed 22.6- and 38.5-fold higher after oral administr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(13 citation statements)
references
References 35 publications
0
13
0
Order By: Relevance
“…AMS, a highly sensitive analytical tool, has enabled for the human AME study to be performed with a trace radioactive dose 9 . As the cost of AMS‐based bioanalysis has continuously decreased, 10,11 many drug development studies have actively adopted the AMS technology 12–14 . This may facilitate faster and earlier decision making during drug development, which leads to shortened overall drug development timeline and increased efficiency 15 …”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…AMS, a highly sensitive analytical tool, has enabled for the human AME study to be performed with a trace radioactive dose 9 . As the cost of AMS‐based bioanalysis has continuously decreased, 10,11 many drug development studies have actively adopted the AMS technology 12–14 . This may facilitate faster and earlier decision making during drug development, which leads to shortened overall drug development timeline and increased efficiency 15 …”
Section: Discussionmentioning
confidence: 99%
“…The objectives of this study were to evaluate the absorption, metabolism, and excretion (AME) of KD101 and to profile its metabolites in humans using the microtracing approach after a single oral administration of KD101 at 400 mg and a microdose of 14 C-KD101 at ~ 35.2 μg (~ 6.81 kBq or 184 nCi). In addition, the effect of pharmacogenomic influence on the human AME of KD101 was explored.…”
Section: A Microtracing Mass Balance Study Of Kd101mentioning
confidence: 99%
See 3 more Smart Citations